Modulation of hepcidin to treat iron deregulation: potential clinical applications
暂无分享,去创建一个
F. Torti | S. Torti | D. Manz | N. Blanchette
[1] M. Nespolo. Iron Metabolism. From Molecular Mechanisms to Clinical Consequences. Fourth Edition. By Robert Crichton. Wiley, 2016. Pp. xviii + 556. Price GBP 135.00 EUR 162.00, hardcover, ISBN 978-1-118-92561-4. , 2017, Acta crystallographica. Section D, Structural biology.
[2] J. Lieberman,et al. Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.
[3] P. Peterson. Abstract 3647: Targeting cancer-induced anemia with hepcidin lowering ALK2 inhibitors , 2015 .
[4] A. Elmarakby,et al. Curcumin Attenuates Iron Accumulation and Oxidative Stress in the Liver and Spleen of Chronic Iron-Overloaded Rats , 2015, PloS one.
[5] N. Munshi,et al. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease , 2015, Clinical Cancer Research.
[6] L. Miller,et al. Hepcidin regulation in prostate and its disruption in prostate cancer. , 2015, Cancer research.
[7] B. Mueller,et al. Anti-repulsive Guidance Molecule C (RGMc) Antibodies Increases Serum Iron in Rats and Cynomolgus Monkeys by Hepcidin Downregulation , 2015, The AAPS Journal.
[8] M. Fleming,et al. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia , 2015, American journal of hematology.
[9] A. Strahs,et al. A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B , 2014 .
[10] Amy Chan,et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.
[11] Daoqiang Zhang,et al. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. , 2014, Cellular signalling.
[12] T. Ganz,et al. Erythroferrone contributes to recovery from anemia of inflammation. , 2014, Blood.
[13] H. Ludwig,et al. Abstract 3847: The anti-hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study , 2014 .
[14] Léon Kautz. [Erythroferrone, an erythroid regulator of iron metabolism]. , 2014, Medecine sciences : M/S.
[15] T. Ganz,et al. Anemia of inflammation. , 2014, Hematology/oncology clinics of North America.
[16] Hong Liu,et al. Hepcidin and GDF15 in anemia of multiple myeloma , 2014, International Journal of Hematology.
[17] S. Lehmann,et al. Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? , 2014 .
[18] S. Rivella,et al. IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.
[19] R. Peterson,et al. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. , 2014, Blood.
[20] A. Lavecchia,et al. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature , 2014, Expert opinion on therapeutic patents.
[21] F. Roche,et al. Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. , 2014, Blood.
[22] D. Girelli,et al. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. , 2014, Blood.
[23] K. Pallauf,et al. Curcumin may impair iron status when fed to mice for six months , 2014, Redox biology.
[24] J. Machiels,et al. A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.
[25] X. Jiao,et al. Regulation of hepcidin through GDF-15 in cancer-related anemia. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[26] L. Audoly,et al. First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors , 2013, PloS one.
[27] J. Isaacs,et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis , 2013, Arthritis Research & Therapy.
[28] B. Bettencourt,et al. Aln-TMP: A Subcutaneously Administered RNAi Therapeutic Targeting Tmprss6 For The Treatment Of β-Thalassemia , 2013 .
[29] V. Wroblewski,et al. LY2928057, An Antibody Targeting Ferroportin, Is a Potent Inhibitor Of Hepcidin Activity and Increases Iron Mobilization In Normal Cynomolgus Monkeys , 2013 .
[30] Chi-kong Li,et al. A Possible Role Of The Tetraspanin CD9 In Bone Marrow Retention and Engraftment Of Human CD34+ Hematopoietic Stem/Progenitor Cells , 2013 .
[31] C. Begley,et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. , 2013, Blood.
[32] D. Swinkels,et al. Improved Mass Spectrometry Assay For Plasma Hepcidin: Detection and Characterization of a Novel Hepcidin Isoform , 2013, PloS one.
[33] K. Yoshizaki,et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients , 2013, Arthritis Research & Therapy.
[34] Radhika A. Vaishnav,et al. The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease , 2013, Acta neuropathologica communications.
[35] C. Mélot,et al. Hepcidin-25: Measurement by LC-MS/MS in serum and urine, reference ranges and urinary fractional excretion. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[36] J. Turkson,et al. Therapeutic modulators of STAT signalling for human diseases , 2013, Nature Reviews Drug Discovery.
[37] S. Jagannath,et al. A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease , 2013, Clinical Cancer Research.
[38] F. Torti,et al. Iron and cancer: more ore to be mined , 2013, Nature Reviews Cancer.
[39] Vincent Liu,et al. Visitation policies and practices in US ICUs , 2013, Critical Care.
[40] T. Travison,et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells , 2013, Aging cell.
[41] S. Rivella,et al. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. , 2013, The Journal of clinical investigation.
[42] S. Sell,et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. , 2013, Blood.
[43] D. Swinkels,et al. Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia , 2013, Critical Care.
[44] T. Ganz,et al. Cellular Catabolism of the Iron-Regulatory Peptide Hormone Hepcidin , 2013, PloS one.
[45] R. Damoiseaux,et al. High-Throughput Screening of Small Molecules Identifies Hepcidin Antagonists , 2013, Molecular Pharmacology.
[46] S. Milstein,et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. , 2013, Blood.
[47] B. Firwana,et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms , 2013, Therapeutic advances in hematology.
[48] A. Iolascon,et al. Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach , 2012, Haematologica.
[49] D. Swinkels,et al. Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94. , 2012 .
[50] T. Ganz,et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. , 2012, Blood.
[51] J. McMurray,et al. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain , 2012, JAK-STAT.
[52] Elizabeta Nemeth,et al. Hepcidin and iron homeostasis. , 2012, Biochimica et biophysica acta.
[53] T. Tamaki,et al. Estrogen Regulates Hepcidin Expression via GPR30-BMP6-Dependent Signaling in Hepatocytes , 2012, PloS one.
[54] T. Ganz,et al. Inhibition of hepcidin transcription by growth factors , 2012, Hepatology.
[55] M. Lidonnici,et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. , 2012, Blood.
[56] Prabodh K. Kandala,et al. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. , 2012, Drug discoveries & therapeutics.
[57] S. Abramson,et al. 17β-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. , 2012, Endocrinology.
[58] D. Corey,et al. Silencing disease genes in the laboratory and the clinic , 2012, The Journal of pathology.
[59] Shuping Zhang,et al. AG490: an inhibitor of hepcidin expression in vivo. , 2011, World journal of gastroenterology.
[60] Elizabeta Nemeth,et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. , 2011, The Journal of clinical investigation.
[61] B. Bettencourt,et al. Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia , 2011 .
[62] L. Audoly,et al. Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations , 2011 .
[63] C. Hong,et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. , 2011, Blood.
[64] G. Sapkota,et al. The specificities of small molecule inhibitors of the TGFß and BMP pathways. , 2011, Cellular signalling.
[65] Bradley K Weiner,et al. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. , 2011, The spine journal : official journal of the North American Spine Society.
[66] D. Scadden,et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. , 2011, Blood.
[67] F. Zunino,et al. SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis , 2011, Clinical Cancer Research.
[68] D. Girelli,et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. , 2011, Blood.
[69] K. Yoshizaki,et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. , 2010, Blood.
[70] S. Vukicevic,et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. , 2010, Gastroenterology.
[71] Yow-Ming C Wang,et al. Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys , 2010, The AAPS Journal.
[72] M. Willingham,et al. Ferroportin and iron regulation in breast cancer progression and prognosis. , 2010, Science translational medicine.
[73] David P. Davis,et al. A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress. , 2010, Cancer research.
[74] V. Haase. Hypoxic regulation of erythropoiesis and iron metabolism. , 2010, American journal of physiology. Renal physiology.
[75] C. Begley,et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. , 2010, Blood.
[76] D. Gale,et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin , 2010, Haematologica.
[77] P. Brissot,et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form , 2010, Journal of Molecular Medicine.
[78] M. Cornfeld,et al. CNTO328 (Anti-IL-6 mAb) Treatment Is Associated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC). , 2009 .
[79] A. Bosserhoff,et al. Evidence for a Lack of a Direct Transcriptional Suppression of the Iron Regulatory Peptide Hepcidin by Hypoxia-Inducible Factors , 2009, PloS one.
[80] C. Peyssonnaux,et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. , 2009, The Journal of clinical investigation.
[81] M. Roth,et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload , 2009, Nature Genetics.
[82] S. Vukicevic,et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism , 2009, Nature Genetics.
[83] R. D'Agostino,et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. , 2009, Blood.
[84] L. Silvestri,et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. , 2008, Cell metabolism.
[85] Tomokazu Fukuda,et al. BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.
[86] D. Girelli,et al. Immunoassay for human serum hepcidin. , 2008, Blood.
[87] C. Zampronio,et al. SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard , 2008, Proteome Science.
[88] B. Bacon,et al. Hereditary hemochromatosis in the post‐HFE era , 2008, Hepatology.
[89] U. Kobold,et al. Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry. , 2008, Clinical chemistry.
[90] M. Sari,et al. Production of biologically active forms of recombinant hepcidin, the iron‐regulatory hormone , 2008, The FEBS journal.
[91] R. Chung,et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. , 2008, Blood.
[92] N. Andrews,et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA) , 2008, Nature Genetics.
[93] F. Carvalho,et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPα , 2008, Blood.
[94] Y. Aso,et al. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. , 2007, Rapid communications in mass spectrometry : RCM.
[95] D. Girelli,et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. , 2007, Blood.
[96] S. Goh,et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin , 2007, Nature Medicine.
[97] Yin Xia,et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. , 2007, The Journal of clinical investigation.
[98] V. Nizet,et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). , 2007, The Journal of clinical investigation.
[99] David E. Williams,et al. Gene expression analysis during tumor enhancement by the dietary phytochemical, 3,3'-diindolylmethane, in rainbow trout. , 2007, Carcinogenesis.
[100] T. Ganz,et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.
[101] N. Andrews,et al. Hereditary Hemochromatosis Protein, HFE, Interaction with Transferrin Receptor 2 Suggests a Molecular Mechanism for Mammalian Iron Sensing* , 2006, Journal of Biological Chemistry.
[102] K. Chuah,et al. Giant Hepatocellular Adenoma Presenting with Chronic Iron Deficiency Anemia , 2006, The American Journal of Gastroenterology.
[103] H. Umehara,et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. , 2006, Blood.
[104] C. Gabay,et al. Interleukin-6 and chronic inflammation , 2006, Arthritis research & therapy.
[105] C. Rider. Heparin/heparan sulphate binding in the TGF-β cytokine superfamily , 2006 .
[106] Raymond T Chung,et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression , 2006, Nature Genetics.
[107] C. Deng,et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. , 2005, Cell metabolism.
[108] Peng Liu,et al. Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.
[109] G. Giannini,et al. Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting* , 2005, Journal of Biological Chemistry.
[110] A. Donovan,et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. , 2005, Cell metabolism.
[111] E. Beutler,et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. , 2005, Blood cells, molecules & diseases.
[112] Jerry Kaplan,et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.
[113] J. Barton,et al. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. , 2004, Blood.
[114] Elizabeta Nemeth,et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.
[115] A. Niida,et al. USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. , 2004, Biochemical and biophysical research communications.
[116] J. Turkson,et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. , 2004, Molecular cancer therapeutics.
[117] B. Aggarwal,et al. Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells 1 , 2003, The Journal of Immunology.
[118] Elizabeta Nemeth,et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. , 2003, Blood.
[119] T. Ganz. The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease. , 2002, The Israel Medical Association journal : IMAJ.
[120] C. Beaumont,et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[121] Bruno Turlin,et al. A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload* , 2001, The Journal of Biological Chemistry.
[122] Christina H. Park,et al. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver* , 2001, The Journal of Biological Chemistry.
[123] S. Schrier,et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. , 2000, Blood.
[124] Peter Schulz-Knappe,et al. LEAP‐1, a novel highly disulfide‐bonded human peptide, exhibits antimicrobial activity , 2000, FEBS letters.
[125] K. Tarte,et al. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells , 2000, British journal of haematology.
[126] Paolo Gasparini,et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22 , 2000, Nature Genetics.
[127] A. Brownlie,et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter , 2000, Nature.
[128] J. Groopman,et al. Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.
[129] M. C. Ellis,et al. A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.
[130] B. Halliwell,et al. Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. , 1991, Archives of biochemistry and biophysics.
[131] V. Rosen,et al. Novel regulators of bone formation: molecular clones and activities. , 1988, Science.
[132] G. Torri,et al. Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. , 1986, Arzneimittel-Forschung.
[133] V. Siskind,et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. , 1985, Journal of the National Cancer Institute.
[134] D. Weatherall,et al. IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA , 1979, The Lancet.
[135] S. Klußmann,et al. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer(®) therapeutics. , 2015, Drug discovery today.
[136] M. Muckenthaler,et al. Second Round Robin for plasma hepcidin methods : First steps toward harmonization , 2012 .
[137] A. Skerra,et al. Anticalins small engineered binding proteins based on the lipocalin scaffold. , 2012, Methods in enzymology.
[138] K. Miyazono,et al. Bone morphogenetic protein receptors and signal transduction. , 2010, Journal of biochemistry.
[139] E. Valore,et al. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. , 2008, Blood cells, molecules & diseases.
[140] P. Ramos,et al. erythropoiesis in Decreased differentiation of erythroid cells exacerbates ineffective , 2008 .
[141] Charles C Hong,et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. , 2008, Nature chemical biology.
[142] M. Hentze,et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. , 2007, Blood.
[143] C. Rider. Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. , 2006, Biochemical Society transactions.
[144] T. Ganz,et al. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. , 2005, Blood.
[145] Di Chen,et al. Signal transduction and biological functions of bone morphogenetic proteins. , 2004, Frontiers in bioscience : a journal and virtual library.
[146] D. Girelli,et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis , 2003, Nature Genetics.
[147] D. Weatherall,et al. Iron absorption and loading in beta-thalassaemia intermedia. , 1979, Lancet.
[148] H. Levy,et al. Carbon dioxide and oxygen in complex formation with iron and siderophilin, the iron-binding component of human plasma. , 1949, Archives of biochemistry.